Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding
Others
Ratios

Applied Therapeutics (APLT) Other Non Operating Income (2023 - 2025)

Historic Other Non Operating Income for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$7000.0.

  • Applied Therapeutics' Other Non Operating Income rose 6666.67% to -$7000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$61000.0, marking a year-over-year increase of 5704.23%. This contributed to the annual value of -$77000.0 for FY2024, which is 18518.52% down from last year.
  • Applied Therapeutics' Other Non Operating Income amounted to -$7000.0 in Q3 2025, which was up 6666.67% from -$33000.0 recorded in Q2 2025.
  • Applied Therapeutics' Other Non Operating Income's 5-year high stood at $31000.0 during Q1 2023, with a 5-year trough of -$61000.0 in Q4 2023.
  • For the 3-year period, Applied Therapeutics' Other Non Operating Income averaged around -$15181.8, with its median value being -$21000.0 (2024).
  • The largest annual percentage gain for Applied Therapeutics' Other Non Operating Income in the last 5 years was 10655.74% (2024), contrasted with its biggest fall of 58000.0% (2024).
  • Over the past 3 years, Applied Therapeutics' Other Non Operating Income (Quarter) stood at -$61000.0 in 2023, then soared by 106.56% to $4000.0 in 2024, then plummeted by 275.0% to -$7000.0 in 2025.
  • Its Other Non Operating Income stands at -$7000.0 for Q3 2025, versus -$33000.0 for Q2 2025 and -$25000.0 for Q1 2025.